Eaton’s Vehicle Group Launches Electric Vehicle E-Drive Gearing Design, Development and Manufacturing
18.2.2021 14:30:00 EET | Business Wire | Press release
Power management company Eaton today announced its Vehicle Group is developing gearing solutions for electrified vehicles (EVs). Leveraging its expertise in producing transmissions and contract manufactured gear-sets for passenger and commercial vehicles, the Vehicle Group aims to be a leader in the global design, development and supply of EV reduction gearing. The new technology complements Eaton’s eMobility power electronics portfolio in the electrified vehicle powertrain market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210218005131/en/
Eaton’s Vehicle Group can partner with customers on joint-development programs or serve as a single service provider of EV reduction gearing components or systems. (Photo: Business Wire)
Eaton meets electrified vehicle challenges
Automakers face many challenges when developing an electrified vehicle, such as optimizing efficiency, weight, noise, vibration and harshness (NVH), and dealing with packaging constraints. Eaton can help manufacturers meet these challenges by applying its many years of experience and in-house capability in design, validation and manufacturing of high-precision, high-quality gearing systems for transmissions and powertrains.
“We are partnering with OEM customers to leverage our expertise in simulation, design and manufacturing to optimize the efficiency, NVH and weight of high-precision gearing systems tailored to specific customer needs,” said Anthony Cronin, director, EV gearing, Eaton’s Vehicle Group.
Whether a large-scale industrialization project or a niche-market application, Eaton can partner with customers on joint-development programs or serve as a single service provider of EV reduction gearing components or systems. Eaton’s expertise in both design and manufacturing allows us to optimize solutions from a technical, commercial and production aspect, reducing the risk of multi-iteration design and enabling shortened development times.
Eaton transmission experience drives efficiency
Eaton conducts a total system analysis, using state-of-the-art tools and in-house expertise, to design EV gearing solutions that are optimized for efficiency and reliability, with low noise and manufacturing costs. A full-system approach is essential when tailoring a design to a specific customer need, as several factors influence the development of gearing solutions. Chief among those factors are the gears, bearings and lubrication system. To achieve optimization in these three areas, Eaton applies a series of in-house design and manufacturing techniques, including:
- Gear root geometry optimization for maximum strength.
- Micro and macro gear geometry modelling to improve NVH, efficiency and reliability.
- Thrust load and bearing loss minimization to improve reliability and simplify or downsize bearings.
- Simulation and selection of lubrication solutions for full-system reliability and efficiency.
Optimized transmission lowers development costs
Eaton engineers evaluate existing layouts or develop “clean-sheet” solutions that work within a customer’s packaging constraint. The Eaton team also provides solutions for scaling the EV gearing layout for platforms with multiple torque requirements.
By combining system design expertise and manufacturing know-how in high-quality precision gears, Eaton has identified opportunities to improve gearing system efficiency by up to 1 percent, reduce weight by up to 20 percent and size by up to 10 percent. These benefits can be applied to both light-duty and commercial electrified vehicles.
Additionally, by applying its manufacturing expertise, including power honing, power skiving, grinding and superfinishing, Eaton can manage the relative production cost of high-quality precision gears. With electrified vehicles, even small efficiency improvements provide vehicle manufacturers new opportunities to manage vehicle range or improve cost and weight.
“The development of EVs is pushing the boundaries of EV gearing. Reliable, efficient and quiet gearing systems are critical to high-speed motor adoption in electric drives,” said Cronin.
Learn more about Eaton’s Vehicle Group EV Gearing solutions.
Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2020 revenues were $17.9 billion, and we sell products to customers in more than 175 countries. We have approximately 92,000 employees. For more information, visit www.eaton.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005131/en/
Contact information
Thomas Nellenbach
thomasjnellenbach@eaton.com
(216) 333-2876 (cell)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
